These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28814738)

  • 81. Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials.
    Xie Y; Su P; Sun Y; Zhang H; Zhao R; Li L; Meng L
    BMC Nephrol; 2017 Aug; 18(1):272. PubMed ID: 28841848
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The cellular selection between apoptosis and autophagy: roles of vitamin D, glucose and immune response in diabetic nephropathy.
    Hamzawy M; Gouda SAA; Rashid L; Attia Morcos M; Shoukry H; Sharawy N
    Endocrine; 2017 Oct; 58(1):66-80. PubMed ID: 28889337
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease.
    Galassi A; Bellasi A; Ciceri P; Pivari F; Conte F; Cozzolino M
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1073-1084. PubMed ID: 28846459
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Applying proteomics to diagnosis of diabetic kidney disease.
    Moresco RN; De Carvalho JAM
    Expert Rev Proteomics; 2017 Oct; 14(10):841-843. PubMed ID: 28893107
    [No Abstract]   [Full Text] [Related]  

  • 85. Both ligand and VDR expression levels critically determine the effect of 1α,25-dihydroxyvitamin-D
    Yang D; Anderson PH; Wijenayaka AR; Barratt KR; Triliana R; Stapledon CJM; Zhou H; Findlay DM; Morris HA; Atkins GJ
    J Steroid Biochem Mol Biol; 2018 Mar; 177():83-90. PubMed ID: 28887147
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Severe Secondary Hyperparathyroidism in a Hemodialysis Patient: A Case Report from Mongolia.
    Adiya S; Damdinsuren K; Dorj C
    Blood Purif; 2017; 44 Suppl 1():35-40. PubMed ID: 28869940
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
    Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
    Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
    [TBL] [Abstract][Full Text] [Related]  

  • 88. VDR Activation Reduces Proteinuria and High-Glucose-Induced Injury of Kidneys and Podocytes by Regulating Wnt Signaling Pathway.
    Guo J; Lu C; Zhang F; Yu H; Zhou M; He M; Wang C; Zhao Z; Liu Z
    Cell Physiol Biochem; 2017; 43(1):39-51. PubMed ID: 28848172
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism.
    Watanabe H; Sugimoto R; Ikegami K; Enoki Y; Imafuku T; Fujimura R; Bi J; Nishida K; Sakaguchi Y; Murata M; Maeda H; Hirata K; Jingami S; Ishima Y; Tanaka M; Matsushita K; Komaba H; Fukagawa M; Otagiri M; Maruyama T
    Biochem Pharmacol; 2017 Dec; 145():192-201. PubMed ID: 28843775
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Association of Vitamin D Receptor Polymorphisms With the Risk of Nonmelanoma Skin Cancer in Adults.
    Burns EM; Guroji P; Ahmad I; Nasr HM; Wang Y; Tamimi IA; Stiefel E; Abdelgawwad MS; Shaheen A; Muzaffar AF; Bush LM; Hurst CB; Griffin RL; Elmets CA; Yusuf N
    JAMA Dermatol; 2017 Oct; 153(10):983-989. PubMed ID: 28832880
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Understanding the Role of Vitamin D in Heart Failure.
    Tappia PS; Lopez R; Fitzpatrick-Wong S; Ramjiawan B
    Rev Cardiovasc Med; 2023 Apr; 24(4):111. PubMed ID: 39076268
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Physiological Evidence and Therapeutic Outcomes of Vitamin D on Cardiovascular Diseases.
    Zendehdel A; Shakarami A; Moghadam ES
    Curr Cardiol Rev; 2024 Jan; 20(1):. PubMed ID: 38243935
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Tuberculosis and Autoimmunity.
    Belyaeva IV; Kosova AN; Vasiliev AG
    Pathophysiology; 2022 Jun; 29(2):298-318. PubMed ID: 35736650
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Anti-Tumor Effects of Ginsenoside 20(S)-Protopanaxadiol and 1,25-Dihydroxyvitamin D3 Combination in Castration Resistant Prostate Cancer.
    Ben-Eltriki M; Deb S; Shankar G; Meckling G; Hassona M; Yamazaki T; Fazli L; Chin MY; Tomlinson Guns ES
    Medicines (Basel); 2021 Jun; 8(6):. PubMed ID: 34199743
    [TBL] [Abstract][Full Text] [Related]  

  • 95. New Roles for Vitamin D Superagonists: From COVID to Cancer.
    Easty DJ; Farr CJ; Hennessy BT
    Front Endocrinol (Lausanne); 2021; 12():644298. PubMed ID: 33868174
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Active Vitamin D in Chronic Kidney Disease: Getting Right Back Where We Started from?
    Negrea L
    Kidney Dis (Basel); 2019 Mar; 5(2):59-68. PubMed ID: 31019920
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Identification of Novel Non-secosteroidal Vitamin D Receptor Agonists with Potent Cardioprotective Effects and devoid of Hypercalcemia.
    Khedkar SA; Samad MA; Choudhury S; Lee JY; Zhang D; Thadhani RI; Karumanchi SA; Rigby AC; Kang PM
    Sci Rep; 2017 Aug; 7(1):8427. PubMed ID: 28814738
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Nongenomic effects of 1α,25-dihydroxyvitamin D
    Hirota Y; Nakagawa K; Mimatsu S; Sawada N; Sakaki T; Kubodera N; Kamao M; Tsugawa N; Suhara Y; Okano T
    Biochem Biophys Res Commun; 2017 Jan; 483(1):359-365. PubMed ID: 28025137
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects.
    Chen B; Kawai M; Wu-Wong JR
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5949-52. PubMed ID: 24035340
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats.
    Wu-Wong JR; Chen YW; Wessale JL
    Am J Physiol Renal Physiol; 2015 Feb; 308(4):F309-19. PubMed ID: 25503724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.